-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Downgrades Tenax Therapeutics to Neutral, Lowers Price Target to $5

Benzinga·08/11/2026 16:02:35
Listen to the news
Chardan Capital analyst Gautam Chukka downgrades Tenax Therapeutics (NASDAQ:TENX) from Buy to Neutral and lowers the price target from $27 to $5.